This clinical study is to investigate an experimental drug called INCAGN01876 in patients with solid tumours.
INCAGN01876 is an antibody that is designed to help your immune system become more active and possibly fight your cancer. INCAGN01876 recognises and binds (sticks) to a protein on the surface of some immune cells. When INCAGN01876 sticks to this protein, it has the potential to help the function of your immune cells to fight your cancer.
In this research study, INCAGN01876 will be combined with nivolumab and/ or ipilimumab, either at the same time or one after the other. Nivolumab and ipilimumab are also antibodies that stick to and block certain immune cell proteins, which help the body’s immune system fight cancer.
The purposes of this clinical study are to:
(1) look at the safety and tolerability of INCAGN01876
(2) study the way in which INCAGN01876 is broken down and eliminated from the body (called “pharmacokinetics” or “PK”)
(3) learn how INCAGN01876 acts on the body (called “pharmacodynamics” or “PD”)
(4) understand the effects that INCAGN01876 may have on your cancer when combined with nivolumab and/or ipilimumab.
All 3 drugs (INCAGN01876, Nivolumab and Ipilimumab) are immunotherapies that activate the immune system to detect and flight the cancer cells. Both INCAGN01876 and Nivolumab are given every 2 weeks and Ipilimumab is given every 6 weeks, via intravenous infusion. Patients may continue on treatment as long as they are receiving benefit and do not meet withdrawal criteria.
This clinical study is currently recruiting.
If you would like more information, register below or call 1800 727 874.